Objectives: The primary objective of this review is to analyze the effects on body weight of discontinuing therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or tirzepatide in patients treated for obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.